Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) traded down 3.8% during trading on Friday . The stock traded as low as $13.10 and last traded at $13.49. 1,470,132 shares traded hands during trading, an increase of 335% from the average session volume of 337,931 shares. The stock had previously closed at $14.02.
Silverback Therapeutics Stock Down 3.8 %
The company’s 50 day moving average price is $13.10 and its two-hundred day moving average price is $12.94. The firm has a market cap of $486.42 million, a PE ratio of -5.57 and a beta of 0.60.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Read More
- Five stocks we like better than Silverback Therapeutics
- How to Buy Cheap Stocks Step by Step
- Google Is Betting Big on Nuclear Reactors—Should You?
- How to Invest in Biotech Stocks
- Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
